Advertisement

Abstract

Platelet activating factor (PAF) is a low molecular weight, ether-linked phospholipid originally identified as a soluble factor, released from sensitized rabbit basophils during IgE anaphylaxis, that was capable of aggregating rabbit platelets [1, 2]. Cellular sources of PAF subsequently identified include neutrophil [3–8] and eosinophil granulocytes [9, 10], mononuclear phagocytes [4, 5, 11–15], mast cells [16, 17], platelets [18, 19], natural killer cells [20], fibroblasts [21], vascular endothelium [22–24], epithelial cells [25–27] and glomerular mesangial cells [28], as well as brain cells [29, 30], and spermatozoa [31], many of which generate PAF in response to a wide variety of stimuli [32].

Keywords

Platelet Activate Factor Airway Smooth Muscle Rabbit Platelet Platelet Activate Factor Receptor Platelet Activate Factor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barbaro JF, Zvaifler NJ. Antigen induced histamine release from platelets and rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med 1966; 122: 1245–7.PubMedGoogle Scholar
  2. 2.
    Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils, and a platelet-activating factor. J Exp Med 1972; 136: 1356–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Lotner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet activating factor. J Immunol 1980; 124: 676–84.PubMedGoogle Scholar
  4. 4.
    Sanchez Crespo M, Alonso F, Egido J. Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. Immunology 1980; 40: 645–55.Google Scholar
  5. 5.
    Camussi G, Aglietta R, Coda T, Bussolino F, Piacibello W, Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 1981; 42: 191–9.PubMedGoogle Scholar
  6. 6.
    Jouvin-Marche E, Ninio E, Beaurain G, Tence M, Niaudet P, Benveniste J. Biosynthesis of PAF-acether (platelet-activating factor). VII. Precursors of PAF-acether and acetyl-transferase activity in human leukocytes. J Immunol 1984; 133: 892–8.PubMedGoogle Scholar
  7. 7.
    Sisson JH, Prescott SM, McIntyre TM, Zimmerman GA. Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes: correlation of synthesis with release, functional events, and leukotriene B4 metabolism. J Immunol 1987; 138: 3918–26.PubMedGoogle Scholar
  8. 8.
    Nieto ML, Velasco S, Sanchez Crespo M. Biosynthesis of platelet-activating factor in human polymorphonuclear leukocytes. J Biol Chem 1988; 263: 2217–22.PubMedGoogle Scholar
  9. 9.
    Lee T-C, Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem 1984; 259: 5526–30.PubMedGoogle Scholar
  10. 10.
    Asmis R, Jorg A. Calcium-ionophore-induced formation of platelet-activating factor and leukotrienes by horse eosinophils: a comparative study. Eur J Biochem 1990; 187: 475–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Camussi G, Bussolino F, Tetta C, Piacibello W, Aglietta M. Biosynthesis and release of platelet-activating factor from human monocytes. Int Arch Allergy Appl Immunol 1983; 70: 245–51.PubMedCrossRefGoogle Scholar
  12. 12.
    Arnoux B, Jouvin-Marche E, Arnoux A, Benveniste J. Release of PAF-acether from human blood monocytes. Agents Actions 1982; 12: 713–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Arnoux B, Duval D, Benveniste J. Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest 1980; 10: 437–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Arnoux B, Joseph M, Simoes MH, Tonnel A, Duroux P, Capron A, et al. Antigenic release of Paf-acether and β-glucuronidase from alveolar macrophages of asthmatics. Bull Eur Physiopathol Respir 1987; 23: 119–24.PubMedGoogle Scholar
  15. 15.
    Elstad MR, Prescott SM, McIntyre TM, Zimmerman GA. Synthesis and release of plaatelet-activating factor by stimulated mononuclear phagocytes. J Immunol 1988; 140: 1618–24.PubMedGoogle Scholar
  16. 16.
    Schleimer RP, MacGlashan DWJ, Peters SP, Pinckard RN, Adkinson NF, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986; 133: 614–7.PubMedGoogle Scholar
  17. 17.
    Triggiani M, Hubbard WC, Chilton FH. Synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol 1990; 144: 4773–80.PubMedGoogle Scholar
  18. 18.
    Touqui L, Hatmi M, Vargaftig BB. Human platelets stimulated by thrombin produce platelet-activating factor when the degrading enzyme acetylhydrolase is blocked. Biochem J 1985; 229: 811–6.PubMedGoogle Scholar
  19. 19.
    Alam I, Silver MJ. Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. Thromb Res 1987; 45: 311–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Malavasi F, Tetta C, Funaro A, Bellone G, Ferrero E, Franzone AC, et al. Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes. Proc Natl Acad Sci 1986; 83: 2443–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Michel L, Denizot Y, Thomas Y, Jean-Louis F, Pitton C, Benveniste J, et al. Biosynthesis of Paf-acether by human skin fibroblasts in vitro. J Immunol 1988; 141: 948–53.PubMedGoogle Scholar
  22. 22.
    Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F, et al. The release of platelet-activating factor from human endothelial cells in culture. J immunol 1983; 131: 2397–403.PubMedGoogle Scholar
  23. 23.
    Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci 1984; 81: 3534–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Bussolino F, Breviario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin-1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest 1986; 77: 2027–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Salari H, Wong A. Generation of platelet activating factor (PAF) by a human lung epithelial cell line. Eur J Pharmacol 1990; 175: 253–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Ferraris L, Karmeli F, Eliakim R, Klein J, Fiocchi C, Rachmilewitz D. Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut 1993; 34: 665–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Holtzman MJ, Ferdman B, Bohrer A, Turk J. Synthesis of the 1-O-hexadecyl molecular species of platelet-activating factor by airway epithelial and vascular endothelial cells. Biochem Biophys Res Commun 1991; 177: 357–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Schlondorff D, Goldwasser P, Neuwirth R, Satriano JA, Clay KL. Production of platelet-activating factor in glomeruli and culture glomerular mesangial cells. Am J Physiol 1986; 250: 1123–7.Google Scholar
  29. 29.
    Sogos V, Bussolino F, Pilia E, Torelli S, Gremo F. Acetylcholine-induced production of platelet-activating factor by human fetal brain cells in culture. J Neurosci Res 1990; 27: 706–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Yue TL, Lysko PG, Feuerstein G. Production of platelet-activating factor from rat cerebellar granule cells in culture. J Neurochem 1990; 54: 1809–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Baldi E, Falsetti C, Gervasi G, Carloni V, Casano R, et al. Stimulation of platelet-activating factor synthesis by progesterone and A23187 in human spermatozoa. Biochem J 1993; 292: 209–16.PubMedGoogle Scholar
  32. 32.
    Bratton D, Henson PM. Cellular origins of PAF. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 23–57.Google Scholar
  33. 33.
    Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor: evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254: 9355–8.PubMedGoogle Scholar
  34. 34.
    Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun 1979; 90: 1194–200.PubMedCrossRefGoogle Scholar
  35. 35.
    Benveniste J, Tence M, Varenne P, Bidault C, Boullet C, Polonsky J. Semi-synthèse et structure proposée du facteur activant les plaquettes (PAF): Paf-acether, un alkyl ether analogue de la phosphatidylcholine. C R Acad Sci 1979; 289: 1037–40.Google Scholar
  36. 36.
    Sugiura T, Waku K. Composition of alkyl ether-linked phospholipids in mammalian tissues. In: Snyder F, editor. Platelet-activating Factor and Related Lipid Mediators. New York: Plenum, 1987: 55–85.CrossRefGoogle Scholar
  37. 37.
    Lee TC. Enzymatic control of the cellular levels of platelet activating factor. In: Snyder F, editor. Platelet-activating Factor and Related Mediators. New York: Plenum, 1987: 115–33.CrossRefGoogle Scholar
  38. 38.
    Ojima-Uchiyama A, Masuzawa Y, Sugiura T, Waku K, Saito H, Yui Y, et al. Phospholipid analysis of human eosinophils: High levels of alkylacylglycerophosphocholine (PAF precursor). Lipids 1988; 23: 815–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Blank ML, Spector AA, Kaduce TL, Snyder F. Composition and incorporation of [3H]arachidonic acid into molecular species of phospholipid classes by cultured human endothelial cells. Biochim Biophys Acta 1986; 877: 211–5.PubMedGoogle Scholar
  40. 40.
    Wykle RL, Malone B, Snyder F. Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem 1980; 255: 10256–60.PubMedGoogle Scholar
  41. 41.
    Lee T-C. Biosynthesis of platelet activating factor: Substrate specificity of 1-alkyl-lyso-2-sn-glycero-3-phosphocholine: acetyl-CoA acetyltransferase in rat spleen microsomes. J Biol Chem 1985; 260: 10952–5.PubMedGoogle Scholar
  42. 42.
    Gomez-Cambronero J, Mato JM, Vivanco F, Sanchez-Crespo M. Phosphorylation of partially purified 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine:Acetyl-CoA acetyltransferase from rat spleen. Biochem J 1987; 245: 893–8.PubMedGoogle Scholar
  43. 43.
    Renooij W, Snyder F. Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. Biochem Biophys Acta 1981; 663: 545–56.PubMedGoogle Scholar
  44. 44.
    Woodard DS, Lee T-C, Snyder F. The final step in the de novo biosynthesis of platelet activating factor: properties of a unique CDP-choline:1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase in microsome from the renal inner medulla of rats. J Biol Chem 1993; 262: 2520–7.Google Scholar
  45. 45.
    Fernandez-Gallardo S, Gijon MA, Garcia Md-C, Cano E, Sanchez Crespo M. Biosynthesis of platelet-activating factor in glandular gastric mucosa: Evidence for the involvement of the de novo pathway and modulation by fatty acids. Biochem J 1988; 254: 707–14.PubMedGoogle Scholar
  46. 46.
    Alonso F, Gil MG, Sanchez Crespo M, Mato JM. Activation of 1-alkyl-2-lyso-glycero-3-phosphocholine: acetyl-CoA transferase during phagocytosis in human polymorphonuclear leukocytes. J Biol Chem 1982; 257: 3376–8.PubMedGoogle Scholar
  47. 47.
    Snyder F, Lee T-C, Blank M, Malone B, Woodard D, Robinson M. Platelet activating factor (PAF): alternative pathways of biosynthesis, the mechanism of inactivation, and the reacylation of lyso-PAF with arachidonate. Adv Prost Thromb Leuk Res 1985; 15: 693–6.Google Scholar
  48. 48.
    Domenech C, Machade-De Domenech E, Soling H-D. Regulation of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase (lyso-PAF-acetyltransferase) in exocrine glands: evidence for an inactivation via phosphorylation by calcium/calmodulin-dependent protein kinase. J Biol Chem 1987; 262: 5671–6.PubMedGoogle Scholar
  49. 49.
    Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/catechin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166: 1390–404.PubMedCrossRefGoogle Scholar
  50. 50.
    Bussolino F, Camussi G, Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1α. J Biol Chem 1988; 263: 11856–61.PubMedGoogle Scholar
  51. 51.
    Doebber TW, Wu MS. Platelet-activating factor (PAF) stimulates the PAF-synthesizing enzyme acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase and PAF synthesis in neutrophils. Proc Natl Acad Sci 1987; 84: 7557–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Snyder F. The significance of dual pathways for the biosynthesis of platelet activating factor: 1-alkyl-2-lyso-.M-glycero-3-pnosphate as a branch point. In: Winslow CM, Lee ML, editors. New Horizons in Platelet Activating Factor Research. New York: John Wiley, 1987: 13–26.CrossRefGoogle Scholar
  53. 53.
    Page CP. Platelet-activating factor. In: Kay AB, Austen KF, Lichtenstein LM, editors. Asthma: Basic Mechanisms and Clinical Management. London: Academic Press, 1988: 283–304.Google Scholar
  54. 54.
    McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest 1981; 67: 903–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Kornecki E, Ehrlich YH, Lenox RH. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science 1985; 226: 1454–6.CrossRefGoogle Scholar
  56. 56.
    Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979; 279: 799–800.PubMedCrossRefGoogle Scholar
  57. 57.
    Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-3-phosphorylcholine (platelet activating factor). J Immunol 1981; 127: 1250–5.PubMedGoogle Scholar
  58. 58.
    Gorman RR, Morton DR, Hopkins NK, Lin AH. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes. Adv Prost Thromb Leuk Res 1983; 12: 57–63.Google Scholar
  59. 59.
    Dewald B, Baggiolini M. Platelet-activating factor as a stimulus of exocytosis in human neutrophils. Biochim Biophys Acta 1986; 888: 42–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Bruijnzeel PLB, Koenderman L, Kok PTM, Hamelink ML, Verhagen J. Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmacol Res Commun 1986; 18 (Suppl.): 61–9.CrossRefGoogle Scholar
  61. 61.
    MacDonald AJ, Moqbel R, Wardlaw AJ, Kay AB. Platelet activating factor (PAF) enhances eosinophil cytotoxicity in vitro. J Allergy Clin Immunol 1986; 77: 227.Google Scholar
  62. 62.
    Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor: a potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986; 78: 1701–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Hartung H-P. Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages: Studies on PGE2, TxB2 and O2-production, spreading, and the influence of calmodulin inhibitor W-7. FEBS Lett 1983; 160: 209–12.PubMedCrossRefGoogle Scholar
  64. 64.
    Hayashi H, Kudo I, Inoue K, Onozaki K, Tsushima S, Nomura H, et al. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists. J Biochem 1985; 97: 1737–45.PubMedGoogle Scholar
  65. 65.
    Pustynnikov MG, Porodenko NV, Makarova OV, Kozyukov AV, Moskaleva EY, Sokolovsky AA, et al. Platelet-activating factor stimulates receptor-mediated formation of reactive oxygen intermediates in human monocytes. Lipids 1991; 26: 1214–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Ruis NM, Rose JK, Valone FH. Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Lipids 1991; 26: 1060–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Bussolino F, Camussi G, Aglietta M, Braquet P, Bosia A, Pescarmona G, et al. Human endothelial cells are targets for platelet-activating factor. J Immunol 1987; 139: 2439–46.PubMedGoogle Scholar
  68. 68.
    Churchill L, Chilton FH, Proud D. Interaction of platelet-activating factor with cultured guinea pig tracheal epithelial cells. Biochem J 1991; 276: 593–8.PubMedGoogle Scholar
  69. 69.
    Salari H Schellenberg RR. Stimulation of human airway epithelial cells by platelet activating factor (PAF) and arachidonic acid produces 15-hydroxyeicosatetraenoic acid (15-HETE) capable of contracting bronchial smooth muscle. Pulm Pharmacol 1991; 4: 1–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Adler KB, Akley NJ, Glasgow WC. Platelet-activating factor provokes release of mucin-like glycoproteins from guinea pig respiratory epithelial cells via a lipoxygenase-dependent mechanism. Am J Respir Cell Mol Biol 1992; 6: 550–6.PubMedGoogle Scholar
  71. 71.
    Rola-Pleszczynski M, Pignol B, Pouliot C, Braquet P. Inhibition of human lymphocyte proliferation and interleukin-2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021. Biochem Biophys Res Commun 1987; 142: 754–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Behrens TW, Goodwin JS. Control of human T cell proliferation by platelet-activating factor. Int J Immunopharmacol 1990; 12: 175–84.PubMedCrossRefGoogle Scholar
  73. 73.
    Rola-Pleszczynski M. Immune modulation of PAF: effects on lymphocyte and monocyte function. In: Braquet P, editor. PAF and Cell Immunology: New Trends in Lipid Mediators Research. Basel: Karger, 1988: 30–7.Google Scholar
  74. 74.
    Venge P, Carlson M. Eosinophil granule proteins in bronchial asthma. In: Kay AB, editor. Eosinophils, Allergy and Asthma. Oxford: Blackwell, 1990: 96–105.Google Scholar
  75. 75.
    Barnes PJ, Chung KF, Page CP. PAF and lung disease. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 158–78.Google Scholar
  76. 76.
    Schellenberg RR, Ishida K. Airway hyperresponsiveness: Role of platelet-activating factor. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, editors. Platelet-Activating Factor in Endotoxin and Immune Diseases. New York: Marcel Dekker, 1990: 351–65.Google Scholar
  77. 77.
    Feuerstein G, Ezra D, Ramwell PW, Letts G, Goldstein R. Platelet-activating factor as a modulator of cardiac and coronary functions. In: Bailey JM, editor. Prostaglandins, Leukotrienes and Lipoxins. New York: Plenum, 1985: 301–10.Google Scholar
  78. 78.
    Feuerstein GZ. PAF and the cardiovascular system. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 138–57.Google Scholar
  79. 79.
    Rosam AC, Wallace JL, Whittle BJR. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 1986; 319: 54–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Gonzalez-Crussi F, Hsueh W. Experimental model of ischemic bowel necrosis: The role of platelet-activating factor and endotoxin. Am J Pathol 1983; 112: 127–35.PubMedGoogle Scholar
  81. 81.
    Whittle BJR, Esplugues JV. PAF and gastrointestinal tract. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 198–219.Google Scholar
  82. 82.
    Camussi G, Montrucchio G, Salvidio G, Tetta C. PAF and renal disease. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 179–97.Google Scholar
  83. 83.
    Johnston JM, Bleasdale JE, Hoffman DR. Functions of PAF in reproduction and development: involvement of PAF in foetal lung maturation and parturition. In: Snyder F, editor. Platelet Activating Factor and Related Lipid Mediators. New York: Plenum, 1987: 375–402.CrossRefGoogle Scholar
  84. 84.
    Kornecki E, Ehrlich YH. PAF and the nervous system. In: Barnes PJ, Page CP, Henson PM, editors. Platelet Activating Factor and Human Disease. Oxford: Blackwell, 1989: 250–67.Google Scholar
  85. 85.
    Kloprogge E, Akkerman JWN. Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. Biochem J 1984; 223: 901–9.PubMedGoogle Scholar
  86. 86.
    Valone FH, Coles E, Reinhold VR, Goetzl EJ. Specific binding of phospholipid platelet-activating factor by human platelets. J Immunol 1982; 129: 1637–41.PubMedGoogle Scholar
  87. 87.
    Ukena D, Dent G, Birke FW, Robaut C, Sybrecht GW, Barnes PJ. Radioligand binding of antagonists of platelet-activating factor to intact human platelets. FEBS Lett 1988; 228: 285–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Burgers JA, Akkerman JW. Regulation of the receptor for platelet-activating factor on human platelets. Biochem J 1993; 191: 157–61.Google Scholar
  89. 89.
    Tahraoui L, Floch A, Cavero I. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H] platelet-activating factor binding in human platelets. J Pharmacol Exp Ther 1990; 252: 1221–7.PubMedGoogle Scholar
  90. 90.
    Hussaini IM, Shen TY. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor. Biochem Biophys Res Commun 1989; 161: 23–30.PubMedCrossRefGoogle Scholar
  91. 91.
    Hwang S-B, Lee C-SC, Cheah MJ, Shen TY. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry 1983; 22: 4756–63.PubMedCrossRefGoogle Scholar
  92. 92.
    Valone FH, Ruis NM. Platelet-activating factor binding to human platelet membranes. Biotechnol Appl Biochem 1986; 8: 465–70.PubMedGoogle Scholar
  93. 93.
    Homma H, Tokumura A, Hanahan DJ. Binding and internalization of platelet-activating factor 1-O-alkyl-2-acetyl-3-sn-glycero-3-phosphocholine in washed rabbit platelets. J Biol Chem 1987; 262: 10582–7.PubMedGoogle Scholar
  94. 94.
    Hwang S-B, Lam M-H. L-659,989: a useful probe in the detection of multiple conformational states of PAF receptors. Lipids 1991; 26: 1148–53.PubMedCrossRefGoogle Scholar
  95. 95.
    Terashita Z, Imura Y, Nishikawa K. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol 1985; 34: 1491–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Paulson SK, Wolf JL, Novotney-Barry A, Cox CP. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor. Proc Soc Exp Biol Med 1990; 195: 247–54.PubMedGoogle Scholar
  97. 97.
    Robaut C, Durand G, James C, Lave D, Sedivy P, Floch A, et al. PAF binding sites: Characterization by [3H]52770 RP, a pyrrolo[1,2,c]thiazole derivative, in rabbit platelets. Biochem Pharmacol 1987; 36: 3221–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Hwang S-B, Lam M-H, Chang MN. Specific binding of [3H]dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor. J Biol Chem 1986; 261: 13720–6.PubMedGoogle Scholar
  99. 99.
    Janero DR, Burghardt B, Burghardt C. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. Thromb Res 1988; 50: 789–802.PubMedCrossRefGoogle Scholar
  100. 100.
    Tahraoui L, Floch A, Mondot S, Cavero I. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: Counterparts of platelet-activating factor receptors mediating platelet aggregation. Mol Pharmacol 1988; 34: 145–51.PubMedGoogle Scholar
  101. 101.
    Inarrea P, Gomez-Cambronero J, Nieto M, Sanchez Crespo M. Characteristics of the binding of platelet-activating factor to platelets of different animal species. Eur J Pharmacol 1984; 105: 309–15.PubMedCrossRefGoogle Scholar
  102. 102.
    O’Flaherty JT, Surles JR, Redman J, Jacobson D, Piantadosi C, Wykle RL. Binding and metabolism of platelet-activating factor by human neutrophils. J Clin Invest 1986; 78: 381–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Marquis O, Robaut C, Cavero I. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J Pharmacol Exp Ther 1988; 244: 709–15.PubMedGoogle Scholar
  104. 104.
    Dent G, Ukena D, Chanez P, Sybrecht GW, Barnes PJ. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086: correlation between receptor binding and function. FEBS Lett 1989; 244: 365–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Ukena D, Dent G, Chanez P, Barnes PJ, Sybrecht GW. Charakterisierung der Plättchen-aktivierenden Faktor (PAF)-rezeptoren in neutrophilen und eosinophilen Granulozyten. Pneumologie 1990; 44 (Suppl. 1): 531–2.PubMedGoogle Scholar
  106. 106.
    Ng DS, Wong K. Specific binding of platelet-activating factor (PAF) by human peripheral blood mononuclear leukocytes. Biochem Biophys Res Commun 1988; 155: 311–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Hayashi H, Kudo I, Nojima S, Inoue K. Biological response of guinea pig peritoneal macrophages to platelet-activating factor. Lipids 1991; 26: 1193–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Mol Pharmacol 1993; 43: 302–12.PubMedGoogle Scholar
  109. 109.
    Hwang S-B. High affinity receptor binding of platelet-activating factor in rat peritoneal polymorphonuclear leukocytes. Eur J Pharmacol 1991; 196: 169–75.PubMedCrossRefGoogle Scholar
  110. 110.
    Ukena D, Kroegel C, Dent G, Yukawa T, Sybrecht GW, Barnes PJ. PAF receptors on eosinophils: identification with a novel ligand, [3H]WEB 2086. Biochem Pharmacol 1989; 38: 1702–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Dent G, Barnes PJ. Platelet activating factor stimulates a receptor-coupled membrane GTPase in guinea pig eosinophils. Life Sci 1993; 52: 1633–40.PubMedCrossRefGoogle Scholar
  112. 112.
    Vallari DS, Austinhirst R, Snyder F. Development of specific functionally active receptors for platelet-activating factor in HL-60 cells following granulocytic differentiation. J Biol Chem 1990; 265: 4261–5.PubMedGoogle Scholar
  113. 113.
    Ye RD, Prossnitz ER, Zou AH, Cochrane CG. Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem Biophys Res Commun 1991; 180: 105–11.PubMedCrossRefGoogle Scholar
  114. 114.
    Lee JS, Ong R, Yoo TJ, Chiang T. Binding of platelet activating factor by isolated membranes from U937 cells. Cell Immunol 1990; 125: 415–25.PubMedCrossRefGoogle Scholar
  115. 115.
    Valone FH. Identification of platelet-activating factor receptors in P388D1 murine macrophages. J Immunol 1988; 140: 2389–94.PubMedGoogle Scholar
  116. 116.
    Travers JB, Shaw JE, Li Q, Kniss DA, Fertel RH. Evidence for platelet-activating factor receptors in several B lymphoblastoid cell lines. Life Sci 1991; 49: 1755–60.PubMedCrossRefGoogle Scholar
  117. 117.
    Travers JB, Li Q, Kniss DA, Fertel RH. Identification of functional platelet-activating factor receptors in Raji lympoblasts. J Immunol 1989; 143: 3708–13.PubMedGoogle Scholar
  118. 118.
    Hwang S-B, Lam M-H, Shen TY. Specific binding sites for platelet activating factor in human lung tissues. Biochem Biophys Res Commun 1985; 128: 972–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Dent G, Ukena D, Sybrecht GW, Barnes PJ. [3H]WEB 2086 labels platelet activating factor receptors in guinea pig and human lung. Eur J Pharmacol 1989; 169: 313–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Gomez J, Bloom JW, Yamamura HI, Halogen M. Characterization of receptors for platelet-activating factor in guinea pig lung membranes. Am J Respir Cell Mol Biol. 1990; 3: 259–64.PubMedGoogle Scholar
  121. 121.
    Goldie RG, Pedersen KE, Rigby PJ, Paterson JW. PAF receptors in guinea-pig and human lung. Agents Actions 1990; Suppl. 31: 243–6.Google Scholar
  122. 122.
    Herbert JM. Characterization of specific binding sites of 3H-labelled platelet-activating factor ([3H]PAF) and a new antagonist, [3H]SR 27417, on guinea-pig tracheal epithelial cells. Biochem J 1992; 284: 201–6.PubMedGoogle Scholar
  123. 123.
    Sun DX, Rui YC, Zeng GQ, Zhu J, Shen YA. Specific binding sites of platelet activating factor on the intact bovine cerebral microvascular endothelial cells and antagonism of drugs. Chung Kuo Yao Li Hsueh Pao 1992; 13: 326–9.PubMedGoogle Scholar
  124. 124.
    Tanako T, Honda Z, Watanabe T, Uchida S, Shimizu T, Kurokawa K. Demonstration of platelet activating factor receptor in guinea pig kidney. Biochem Biophys Res Commun 1991; 177: 54–60.CrossRefGoogle Scholar
  125. 125.
    Yang YQ, Kudolo GB, Harper MJ. Binding of platelet-activating factor to oviductal membranes during early pregnancy in the rabbit. J Lipid Mediat 1992; 5: 77–96.PubMedGoogle Scholar
  126. 126.
    Hwang S-B. Specific receptor sites for platelet activating factor on rat liver plasma membranes. Arch Biochem Biophys 1987; 257: 339–44.PubMedCrossRefGoogle Scholar
  127. 127.
    Chao W, Liu H, De Buysere M, Hanahan DJ, Olson MS. Identification of receptors for platelet-activating factor in rat Kupffer cells. J Biol Chem 1989; 264: 13591–8.PubMedGoogle Scholar
  128. 128.
    Domingo MT, Chabrier PE, Van Delft JL, Verbeij NL, Van Haeringen NJ, Braquet P. Characterization of specific binding sites for PAF in the iris and ciliary body of rabbit. Biochem Biophys Res Commun 1989; 160: 250–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Van Delft JL, Van Haeringen NJ, Verbeij NL, Domingo MT, Chabrier PE, Braquet P. Specific receptor sites for PAF in iris and ciliary body of the rabbit eye. Curr Eye Res 1988; 7: 1063–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Domingo MT, Spinnewyn B, Chabrier PE, Braquet P. Presence of specific binding sites for platelet-activating factor (PAF) in brain. Biochem Biophys Res Commun 1988; 151: 730–6.PubMedCrossRefGoogle Scholar
  131. 131.
    Junier MP, Tiberghien C, Rougeot C, Fafeur V, Dray F. Inhibitory effect of platelet-activating factor (PAF) on luteinizing hormone-releasing hormone and somatostatin release from rat median eminence in vitro correlated with the characterization of specific PAF receptor sites in rat hypothalamus. Endocrinology 1988; 123: 72–80.PubMedCrossRefGoogle Scholar
  132. 132.
    Korth R, Hirafuji M, Keraly CL, Delautier D, Bidault J, Benveniste J. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells. Br J Pharmacol 1989; 98: 653–61.PubMedGoogle Scholar
  133. 133.
    Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF). II. Interactions with PAF and benzodiazepine receptors. Prostaglandins 1990; 40: 571–83.PubMedCrossRefGoogle Scholar
  134. 134.
    Schwinger RH, Bohm M, La Rosee K, Erdmann E. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium. Am Heart J 1992; 124: 320–30.PubMedCrossRefGoogle Scholar
  135. 135.
    Bachelet M, Adolfs MJP, Masliah J, Bereziat G, Vargaftig BB, Bonta IL. Interaction between PAF-acether and drugs that stimulate cyclic AMP in guinea-pig aveolar macrophages. Eur J Pharmacol 1988; 149: 73–8.PubMedCrossRefGoogle Scholar
  136. 136.
    Hwang S-B, Lam M-H, Pong S-S. Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes. J Biol Chem 1986; 261: 532–7.PubMedGoogle Scholar
  137. 137.
    Chau LY, Jii YJ. Characterization of 3H-labelled platelet activating factor receptor complex solubilized from rabbit platelet membranes. Biochim Biophys Acta 1988; 970: 103–12.PubMedCrossRefGoogle Scholar
  138. 138.
    Hwang S-B. Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes. J Biol Chem 1988; 263: 3225–33.PubMedGoogle Scholar
  139. 139.
    Ng DS, Wong K. GTP regulation of platelet-activating factor binding to human neutrophil membranes. Biochem Biophys Res Commun 1986; 141: 353–9.PubMedCrossRefGoogle Scholar
  140. 140.
    Agrawal DK, Ali N, Numao T. PAF receptors and G-proteins in human blood eosinophils and neutrophils. J Lipid Mediat 1992; 5: 101–4.PubMedGoogle Scholar
  141. 141.
    Hwang S-B, Lam M-H, Hsu AH. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors. Mol Pharmacol 1989; 35: 48–58.PubMedGoogle Scholar
  142. 142.
    Votta B, Mong S. Binding of radiolabeled antagonist to platelet-activating factor receptor in human lung membranes: shifting of agonist binding affinity states by cations and guanine nucleotide. Life Sci 1990; 46: 309–13.PubMedCrossRefGoogle Scholar
  143. 143.
    Ng DS, Wong K. Effect of sulfhydryl reagents on PAF binding to human neutrophils and platelets. Eur J Pharmacol 1988; 154: 47–52.PubMedCrossRefGoogle Scholar
  144. 144.
    Hwang S-B, Lam M-H. Species difference in the specific receptors of platelet activating factor. Biochem Pharmacol 1986; 35: 4511–8.PubMedCrossRefGoogle Scholar
  145. 145.
    Stewart AG, Dusting GJ. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages. Br J Pharmacol 1988; 94: 1225–33.PubMedGoogle Scholar
  146. 146.
    Stewart AG, CV 6209 is a non-competitive antagonist of platelet-activating factor receptors on guinea-pig resident peritoneal macrophages. Clin Exp Pharmacol Physiol 1989; 16: 813–20.PubMedCrossRefGoogle Scholar
  147. 147.
    Kroegel C, Yukawa T, Westwick J, Barnes PJ. Evidence for two platelet activating factor receptors on eosinophils: Dissociation between PAF-induced intracellular calcium mobilization degranulation and Superoxide anion generation in eosinophils. Biochem Biophys Res Commun 1989; 162: 511–21.PubMedCrossRefGoogle Scholar
  148. 148.
    Morrison WJ, Shukla SD. Desensitization of receptor-coupled activation of phosphoinositide-specific phospholipase C in platelets: Evidence for distinct mechanisms for platelet-activating factor and thrombin. Mol Pharmacol 1988; 33: 58–63.PubMedGoogle Scholar
  149. 149.
    O’Flaherty JT, Nishihira J. Arachidonate metabolites, platelet-activating factor, and the mobilization of protein kinase C in human polymorphonuclear neutrophils. J Immunol 1987; 138: 1889–95.PubMedGoogle Scholar
  150. 150.
    O’Flaherty JT, Redman JF, Jacobson DP, Rossi AG. Stimulation and priming of protein kinase C translocation by a Ca2+ transient-independent mechanism: studies in human neutrophils challenged with platelet-activating factor and other receptor agonists. J Biol Chem 1990; 265: 21619–23.PubMedGoogle Scholar
  151. 151.
    Gay JC. Mechanism and regulation of neutrophil priming by platelet-activating factor. J Cell Physiol 1993; 156: 189–97.PubMedCrossRefGoogle Scholar
  152. 152.
    Chao W, Liu H, Hanahan DJ, Olson MS. Regulation of platelet-activating factor receptors in rat Kupffer cells. J Biol Chem 1989; 264: 20448–57.PubMedGoogle Scholar
  153. 153.
    Schwerstschlag US, Whorton AR. Platelet-activating factor-induced homologous and heterologous desensitization in cultured vascular smooth muscle cells. J Biol Chem 1988; 263: 13791–6.Google Scholar
  154. 154.
    Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 1991; 349: 342–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Chao W, Liu H, Hanahan DJ, Olson MS. Regulation of platelet-activating factor receptor and PAF receptor-mediated arachidonic acid release by protein kinase C activation in rat Kupffer cells. Arch Biochem Biophys 1990; 282: 188–97.PubMedCrossRefGoogle Scholar
  156. 156.
    Yamazaki M, Gomez-Cambronero J, Durstin M, Molski TF, Becker EL, Sha’afi RI. Phorbol 12-myristate 13-acetate inhibits binding of leukotriene B4 and platelet-activating factor and the responses they induce in neutrophils: site of action. Proc Natl Acad Sci 1989; 86: 5791–4.PubMedCrossRefGoogle Scholar
  157. 157.
    O’Flaherty JT, Jacobson DP, Redman JF. Bidirectional effects of protein kinase C activators: studies with human neutrophils and platelet-activating factor. J Biol Chem 1989; 264: 6836–43.PubMedGoogle Scholar
  158. 158.
    Chao W, Liu H, Hanahan DJ, Olson MS. Protein tyrosine phosphorylation and regulation of the receptor for platelet-activating factor in rat Kupffer cells: effect of sodium vanadate. Biochem J 1992; 288: 777–84.PubMedGoogle Scholar
  159. 159.
    Bazan NG, Squinto SP, Braquet P, Panetta T, Marcheselli VL. Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: intracellular PAF-binding sites and activation of a fos/jun/AP-1 transcriptional signaling system. Lipids 1991; 26: 1236–42.PubMedCrossRefGoogle Scholar
  160. 160.
    Marcheselli VL, Rossowska MJ, Domingo MT, Braquet P, Bazan NG. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem 1990; 265: 9140–5.PubMedGoogle Scholar
  161. 161.
    Nishihira J, Ishibashi T, Imai Y, Muramatsu T, Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. Tohoku J Exp Med 1985; 147: 145–52.PubMedCrossRefGoogle Scholar
  162. 162.
    Valone FH. Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-acetyl-SN-glycero-3-phosphorylcholine. Immunology 1984; 52: 169–74.PubMedGoogle Scholar
  163. 163.
    Dive G, Godfroid JJ, Lamotte-Brasseur J, Batt JP, Heymans F, Dupont L, et al. PAF-receptor. 1. ‘Cacheoreilles’ effect of selected high-potency platelet-activating factor (PAF) antagonists. J Lipid Mediat 1989; 1: 201–15.PubMedGoogle Scholar
  164. 164.
    Godfroid JJ, Dive G, Lamotte-Brasseur J, Batt JP, Heymans F. PAF receptor structure: a hypothesis. Lipids 1991; 26: 1162–6.PubMedCrossRefGoogle Scholar
  165. 165.
    Lamotte-Brasseur J, Heymans F, Dive G, Lamouri A, Batt JP, Redeuilh C, et al. PAF receptor and “Cacheoreilles” effect: simple PAF antagonists. Lipids 1991; 26: 1167–71.PubMedCrossRefGoogle Scholar
  166. 166.
    Rogers JE, Duronio V, Wong SI, McNeil M, Salari H. Solubilization of a functionally active platelet-activating factor receptor from rabbit platelets. Biochem J 1991; 278: 405–10.PubMedGoogle Scholar
  167. 167.
    Dohlman HG, Caron MG, Lefkowitz RJ. A family of receptors coupled to guanine nucleotide regulatory proteins. Biochemistry 1987; 26: 2657–64.PubMedCrossRefGoogle Scholar
  168. 168.
    Dohlman HG, Caron MG, Strader CD, Amlaiky N, Lefkowitz RJ. Identification and sequence of a binding site peptide of the β2-adrenergic receptor. Biochemistry 1988; 27: 1813–7.PubMedCrossRefGoogle Scholar
  169. 169.
    Dohlman HG, Bouvier M, Benovic JL, Caron MG, Lefkowitz RJ. The multiple membrane spanning topography of the β-adrenergic receptor. J Biol Chem 1987; 262: 14282–8.PubMedGoogle Scholar
  170. 170.
    Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature 1986; 321: 75–9.PubMedCrossRefGoogle Scholar
  171. 171.
    Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 1992; 6: 2296–301.PubMedGoogle Scholar
  172. 172.
    Nakamura M, Honda Z, Izumi T, Sakanaka C, Mutoh H, Minami M, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991; 266: 20400–5.PubMedGoogle Scholar
  173. 173.
    Seyfried CE, Schweickart VL, Godiska R, Gray PW. The human platelet-activating factor receptor gene (PTAFR) contain no introns and maps to chromosome 1. Genomics 1992; 13: 832–4.PubMedCrossRefGoogle Scholar
  174. 174.
    Chase PB, Halonen M, Regan JW. Cloning of a human platelet-activating factor receptor gene: Evidence for an intron in the 5’-untranslated region. Am J Respir Cell Mol Biol 1993; 8: 240–4.PubMedGoogle Scholar
  175. 175.
    Levistre R, Masliah J, Bereziat G. Stimulatory and inhibitory guanine-nucleotide-binding regulatory protein involvement in stimulation of arachidonic-acid release by N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor from guinea-pig alveolar macrophages: differential receptor/G-protein interaction assessed by pertussis and cholera toxins. Eur J Biochem 1993; 213: 295–303.PubMedCrossRefGoogle Scholar
  176. 176.
    Kester M, Thomas CP, Wang J, Dunn MJ. Platelet-activating factor stimulates multiple signaling pathways in cultured rat mesangial cells. J Cell Physiol 1992; 153: 244–55.PubMedCrossRefGoogle Scholar
  177. 177.
    Chau LY, Protein kinase C is not involved in the desensitization of platelet activating factor receptor in rabbit platelets. Lipids 1991; 26: 1076–9.PubMedCrossRefGoogle Scholar
  178. 178.
    Houslay MD, Bojanic D, Wilson A. Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Nj. Biochem J 1986; 234: 737–40.PubMedGoogle Scholar
  179. 179.
    Avdonin PV, Svitina-Ulitina IV, Tkachuk VA. Selective inactivation by endogenous protein kinase C of human platelet high-affinity GTPase coupled with PAF receptors. J Mol Cell Cardiol 1989; 21 (Suppl. 1): 139–43.PubMedCrossRefGoogle Scholar
  180. 180.
    Homma H, Hanahan DJ. Attenuation of platelet activating factor (PAF)-induced stimulation of rabbit platelet GTPase by phorbol ester, dibutyryl cAMP, and desensitization: concomitant effects of PAF receptor binding characteristics. Arch Biochem Biophys 1988; 262: 32–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Nakashima S, Suganuma A, Sato M, Tohmatsu T, Nozawa Y. Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils. J Immunol 1989; 143: 1295–302.PubMedGoogle Scholar
  182. 182.
    Chau LY, Hu CY, Chang WT, Hsu YS. Possible existence of two subsets of platelet-activating factor receptor to mediate polyphosphoinositide breakdown and calcium influx in neuroblastoma x glioma hybrid NG 108-15 cells. J Neurochem 1992; 59: 1090–8.PubMedCrossRefGoogle Scholar
  183. 183.
    Gandhi CR, Hanahan DJ, Olson MS. Two distinct pathways of platelet-activating factor-induced hydrolysis of phosphoinositides in primary cultures of rat Kupffer cells. J Biol Chem 1990; 265: 18234–41.PubMedGoogle Scholar
  184. 184.
    Fruman DA, Gamache DA, Ernest MJ. Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils. Agents Actions 1991; 34: 16–9.PubMedCrossRefGoogle Scholar
  185. 185.
    Williams KA, Haslam RJ. Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor). Biochim Biophys Acta 1984; 770: 216–23.PubMedCrossRefGoogle Scholar
  186. 186.
    Haslam RJ, Vanderwel M. Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). J Biol Chem 1982; 257: 6879–85.PubMedGoogle Scholar
  187. 187.
    Bruijnzeel PLB, Kok PTM, Hamelink ML, Kijne AM, Verhagen J. Platelet-activating factor induces leukotriene C4 synthesis by purified human eosinophils. Prostaglandins 1987; 34: 205–14.PubMedCrossRefGoogle Scholar
  188. 188.
    Levine L. Platelet-activating factor stimulates arachidonic acid metabolism in rat liver cells (C-9 cell line) by a receptor-mediated mechanism. Mol Pharmacol 1988; 34: 793–9.PubMedGoogle Scholar
  189. 189.
    Giembycz MA, Kroegel C, Barnes PJ. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils: concerted biosynthesis of thromboxane A2 and E-series prostaglandins. J Immunol 1990; 144: 3489–97.PubMedGoogle Scholar
  190. 190.
    Fernandez B, Balsinde J. Receptor-mediated activation of arachidonic acid release in mouse peritoneal macrophages is linked to extracellular calcium influx. Biochem Biophys Res Commun 1991; 180: 1036–40.PubMedCrossRefGoogle Scholar
  191. 191.
    Wu T, Lundgren JD, Rieves RD, Doerfler ME, Logun C, Shelhamer JH. Platelet-activating factor stimulates eicosanoid production in cultured feline tracheal explants. Exp Lung Res 1991; 17: 1079–94.PubMedCrossRefGoogle Scholar
  192. 192.
    Glaser KB, Asmis R, Dennis EA. PAF receptor mediated PGE2 production in LPS primed P388D1 macrophage-like cells. Adv Prost Thromb Leuk Res 1991; 21: 249–55.Google Scholar
  193. 193.
    Dhar A, Paul AK, Shukla SD. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: Studies with genistein and monoclonal antibody to phosphotyrosine. Mol Pharmacol 1990; 37: 519–25.PubMedGoogle Scholar
  194. 194.
    Morrison WJ, Shukla SD. Antagonism of platelet activating factor receptor binding and stimulated phosphoinositide-specific phospholipase C in rabbit platelets. J Pharmacol Exp Ther 1989; 250: 831–5.PubMedGoogle Scholar
  195. 195.
    Naccache PH, Molski MM, Volpi M, Becker EM, Sha’afi RI. Unique inhibitory profile of platelet activating factor induced calcium mobilization, polyphosphoinositide turnover and granule enzyme secretion in rabbit neutrophils towards pertussis toxin and phorbol ester. Biochem Biophys Res Commun 1985; 130: 677–84.PubMedCrossRefGoogle Scholar
  196. 196.
    Barzaghi G, Sarau HM, Mong S. Platelet-activating factor-induced phosphoinositide metabolism in differentiated U-937 cells in culture. J Pharmacol Exp Ther 1989; 248: 559–66.PubMedGoogle Scholar
  197. 197.
    Schulam PG, Putcha G, Franklin-Johnson J, Shearer WT. Evidence for a platelet-activating factor receptor on human lymphoblastoid B cells: activation of the phosphatidylinositol cycle and induction of calcium mobilization. Biochem Biophys Res Commun 1990; 166: 1047–52.PubMedCrossRefGoogle Scholar
  198. 198.
    Hallam TJ, Sanchez A, Rink TJ. Stimulus-response coupling in platelets: changes evoked by PAF in cytosoplasmic free calcium monitored with the fluorescent calcium indicator quin 2. Biochem J 1984; 218: 819–27.PubMedGoogle Scholar
  199. 199.
    Valone FH, Johnson B. Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine. J Immunol 1985; 134: 1120–4.PubMedGoogle Scholar
  200. 200.
    Doyle VM, Creba JA, Ruegg UT. Platelet-activating factor mobilises intracellular calcium in vascular smooth muscle stores. FEBS Lett 1986; 197: 13–6.PubMedCrossRefGoogle Scholar
  201. 201.
    von Tscharner V, Prod’hom B, Baggiolini M, Reuter H. Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration. Nature 1986; 324: 369–72.CrossRefGoogle Scholar
  202. 202.
    Yue TL, Gleason MM, Gu JL, Lysko PG, Hallenbeck J, Feuerstein G. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist. J Pharmacol Exp Ther 1991; 257: 374–81.PubMedGoogle Scholar
  203. 203.
    Bkaily G, d’Orleans-Juste P, Naik R, Pérodin J, Stankova J, Abdulnour E, et al. PAF activation of a voltage-gated R-type Ca2+ channel in human and canine aortic endothelial cells. Br J Pharmacol 1993; 110: 519–20.PubMedGoogle Scholar
  204. 204.
    Lapetina EG, Siegel FL. Shape change induced in human platelets by platelet-activating factor. J Biol Chem 1983; 258: 7241–4.PubMedGoogle Scholar
  205. 205.
    Ieyasu H, Takai Y, Kaibuchi K, Sawamura M, Nishizuka Y. A role of calcium-activated, phospholipid-dependent protein kinase in platelet-activating factor-induced serotonin release from rabbit platelets. Biochem Biophys Res Commun 1982; 108: 1701–8.PubMedCrossRefGoogle Scholar
  206. 206.
    Gay JC, Stitt ES. Platelet-activating factor induces protein kinase activity in the particulate fraction of human neutrophils. Blood 1988; 71: 159–65.PubMedGoogle Scholar
  207. 207.
    Thivierge M, Rola-Pleszczynski M. Enhancement of pulmonary nature killer cell activity by platelet activating factor: mechanisms of activation involving Ca2+, protein kinase C, and lipooxygenase products. Am Rev Respir Dis 1991; 144: 272–7.PubMedCrossRefGoogle Scholar
  208. 208.
    Kinnula VL, Adler KB, Ackley NJ, Crapo JD. Release of reactive oxygen species by guinea pig tracheal epithelial cells in vitro. Am J Physiol 1992; 262: L708–12.PubMedGoogle Scholar
  209. 209.
    Kirsch CM, Brokaw JJ, Prow DM, White GW. Mechanism of platelet activating factor-induced vascular leakage in the rat trachea. Exp Lung Res 1992; 18: 447–59.PubMedCrossRefGoogle Scholar
  210. 210.
    Balsinde J, Mollinedo F. Platelet-activating factor synergizes with phorbol myristate acetate in activating phospholipase D in the human promonocytic cell line U937: Evidence for different mechanisms of activation. J Biol Chem 1991; 266: 18726–30.PubMedGoogle Scholar
  211. 211.
    Garay R, Braquet P. Involvement of K+ movements in the membrane signal induced ny PAF-acether. Biochem Pharmacol 1986; 35: 2811–5.PubMedCrossRefGoogle Scholar
  212. 212.
    Ramos-Franco J, Lo CF, Breitwieser GE. Platelet-activating factor receptor-dependent activation of the muscarinic K+ current in bullfrog atrial myocytes. Circ Res 1993; 72: 786–94.PubMedGoogle Scholar
  213. 213.
    Morley J, Page CP, Sanjar S. Pharmacology of the late response to allergen and its relevance to asthma prophylaxis. Int Arch Allergy Appl Immunol 1985; 77: 73–8.PubMedCrossRefGoogle Scholar
  214. 214.
    Chung KF, Barnes PJ. PAF antagonists: Their potential therapeutic role in asthma. Drugs 1988; 35: 93–103.PubMedCrossRefGoogle Scholar
  215. 215.
    Kay AB. Eosinophil chemotactic factors in asthma and allergy. In: Kay AB, editor. Eosinophils, Allergy and Asthma. Oxford: Blackwell, 1990: 31–44.Google Scholar
  216. 216.
    Kroegel C. The role of eosinophils in asthma. Lung 1990; 168 Suppl: 5–17.PubMedCrossRefGoogle Scholar
  217. 217.
    Meade CJ, Heuer H. PAF antagonism as an approach to the treatment of airway hyperreactivity. Am Rev Respir Dis 1991; 143: S79–82.PubMedGoogle Scholar
  218. 218.
    Heuer H, Casals-Stenzel J. Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: Comparison of inhalative and intravenous challenge. Agents Action 1998; Suppl. 23: 207–15.Google Scholar
  219. 219.
    Touvay C, Etienne A, Braquet P. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. Agents Actions 1986; 17: 371–2.PubMedCrossRefGoogle Scholar
  220. 220.
    Coyle AJ, Page CP, Atkinson L, Sjoerdsma K, Touvay C, Metzger WJ. Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol 1989; 84: 960–7.PubMedCrossRefGoogle Scholar
  221. 221.
    Ishida K, Thomson RJ, Beattie LL, Wiggs B, Schellenberg RR. Inhibition of antigen-induced airway hyperresponsiveness, but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet-activating factor. J Immunol 1990; 144: 3907–11.PubMedGoogle Scholar
  222. 222.
    Lefort J, Wal F, Chignard M, Medeiros MC, Vargaftig BB. Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. Agents Actions 1982; 12: 723–5.PubMedCrossRefGoogle Scholar
  223. 223.
    Vargaftig BB, Lefort J, Wai F, Chignard M, Medeiros MC. Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of “platelet-activating factor” (PAF-acether). Eur J Pharmacol 1982; 82: 121–30.PubMedCrossRefGoogle Scholar
  224. 224.
    Lewis AJ, Dervinis A, Chang J. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. Agents Actions 1984; 15: 636–42.PubMedCrossRefGoogle Scholar
  225. 225.
    Bonnet J, Thibaudeau D, Bessin P. Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig. Prostaglandins 1983; 26: 457–66.PubMedCrossRefGoogle Scholar
  226. 226.
    Page CP, Paul W, Morley J. Platelets and bronchospasm. Int Arch Allergy Appl Immunol 1984; 74: 347–50.PubMedCrossRefGoogle Scholar
  227. 227.
    Takizawa H, Ishii A, Suzuki S, Shiga J, Miyamoto T. Bronchoconstriction induction by platelet-activating factor in the guinea pig and its inhibition by CV-3988, a PAF antagonist: Serial changes in findings of lung histology and bronchoalveolar lavage cell population. Int Arch Allergy Appl Immunol 1988; 86: 375–82.PubMedCrossRefGoogle Scholar
  228. 228.
    Anderson G, Fennessy M. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol 1988; 94: 1115–22.PubMedGoogle Scholar
  229. 229.
    Arnoux B, Denjean A, Page CP, Nolibe D, Morley J, Benveniste J. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge: Inhibition by ketotifen. Am Rev Respir Dis 1988; 137: 855–60.PubMedGoogle Scholar
  230. 230.
    Lefer AM, Muller HF, Smith JB. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol 1984; 83: 125–30.PubMedGoogle Scholar
  231. 231.
    Underwood DC, Kadowitz PJ. Analysis of bronchoconstrictor responses to platelet-activating factor in the cat. J Appl Physiol 1989; 67: 377–82.PubMedGoogle Scholar
  232. 232.
    Patterson R, Bernstein PR, Harris KE, Krell RD. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. J Lab Clin Med 1984; 104: 340–5.PubMedGoogle Scholar
  233. 233.
    Patterson R, Harris KE. The activity of aerosolized and intracutaneous synthesis platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. J Lab Clin Min 1983; 102: 933–8.Google Scholar
  234. 234.
    Denjean A, Arnoux B, Masse R, Lockhart A, Benveniste J. Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol 1983; 55: 799–804.PubMedGoogle Scholar
  235. 235.
    Lefort J, Rotilio D, Vargaftig BB. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol 1984; 82: 565–75.PubMedGoogle Scholar
  236. 236.
    Misawa M, Takata T. Effects of platelet-activating factor on rat airways. Jpn J Pharmacol 1988; 48: 7–13.PubMedCrossRefGoogle Scholar
  237. 237.
    Casals-Stenzel J, Frenke J, Friedrich T, Lichey J. Bronchial and vascular effects of Paf in the rat isolated lung are completely blocked by WEB 2086, a novel specific Paf antagonist. Br J Pharmacol 1987; 91: 799–802.PubMedGoogle Scholar
  238. 238.
    Stimler NP, O’Flaherty JT. Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. Am J Pathol 1983; 113: 75–84.PubMedGoogle Scholar
  239. 239.
    Iwama T, Shikada K, Tanaka S. Pharmacological modulation of platelet activating factor (PAF)-induced bronchoconstriction and hypertension in anaesthetized guinea-pigs. J Pharm Pharmacol 1988; 40: 544–7.PubMedCrossRefGoogle Scholar
  240. 240.
    Dyson MC, Bellan JA, Minkes RK, Beckerman RC, Wegmann MJ, Braquet P, et al. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat. J Pharmacol Exp Ther 1990; 255: 1320–7.PubMedGoogle Scholar
  241. 241.
    Smith LJ, Rubin AH, Patterson R. Mechanism of platelet activating factor-induced bronchoconstriction in humans. Am Rev Respir Dis 1988; 137: 1015–9.PubMedGoogle Scholar
  242. 242.
    Stenton SC, Ward C, Duddridge M, Harris A, Palmer JB, Hendrick DJ, et al. The actions of GR32191B, a thromboxane receptor antagonist, on the effects of inhaled PAF on human airways. Clin Exp Allergy 1990; 20: 311–7.PubMedCrossRefGoogle Scholar
  243. 243.
    Goswami SK, Ohashi M, Stathas P, Morom ZM. Platelet-activating factor stimulates secretion of respiratory glycoconjugate from human airways in culture. J Allergy Clin Immunol 1989; 84: 726–34.PubMedCrossRefGoogle Scholar
  244. 244.
    Hamasaki Y, Mojarad M, Saga T, Tai HH, Said SI. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984; 129: 742–6.PubMedGoogle Scholar
  245. 245.
    Pons F, Touvay C, Lejeune V, Carre C, Vilain B, Broquet C, et al. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig. J Lipid Mediat 1989; 1: 329–40.PubMedGoogle Scholar
  246. 246.
    Munoz NM, Kirchhoff CF, Strek ME, Blumenthal RN, Leff AR. Effects of PAF on isolated rat airways perfused with blood-free solution. Am J Physiol 1991; 260: L260–7.PubMedGoogle Scholar
  247. 247.
    Camussi G, Montrucchio G, Antro C, Bussolino F, Tetta C, Emanuelli G. Platelet-activating factor-mediated contraction of rabbit lung strips: Pharmacologic modulation. Immunopharmacology 1983; 6: 87–96.PubMedCrossRefGoogle Scholar
  248. 248.
    Jancar S, Theriault P, Provencal B, Cloutier S, Sirois P. Mechanism of action of platelet-activating factor on guinea-pig lung parenchyma strips. Can J Physiol Pharmacol 1988; 66: 1187–91.PubMedCrossRefGoogle Scholar
  249. 249.
    Touvay C, Vilain B, Etienne A, Sirois P, Borgeat P, Braquet P. Characterization of platelet activating factor (PAF)-acether-induced contractions of guinea-pig lung strips by selected inhibitors of arachidonic acid metabolism and by PAF-acether antagonists. Immunopharmacology 1986; 12: 97–104.PubMedCrossRefGoogle Scholar
  250. 250.
    Smith PF, Palmer JD, Holmes T, Cutcher A, Dunn AM, Halonen M. The responsiveness of rabbit bronchial rings to antigen, AGEPC and histamine. Immunopharmacology 1986; 12: 89–96.PubMedCrossRefGoogle Scholar
  251. 251.
    Jancar S, Theriault P, Braquet P, Sirois P. Comparative effects of platelet activating factor, leukotriene D4 and histamine on guinea pig trachea, bronchus and lung parenchyma. Prostaglandins 1987; 33: 199–208.PubMedCrossRefGoogle Scholar
  252. 252.
    Halonen M, Dunn AM, Palmer JD, McManus LM. Anatomic basis for species differences in peripheral lung strip contraction to PAF. Am J Physiol 1990; 259: L81–6.PubMedGoogle Scholar
  253. 253.
    Popovich KJ, Sheldon G, Mack M, Munoz NM, Denburg P, Blake J, et al. Role of platelets in contraction of canine tracheal muscle elicited by PAF in vitro. J Appl Physiol 1988; 65: 914–20.PubMedGoogle Scholar
  254. 254.
    Jancar S, Theriault P, Lauziere M, Braquet P, Sorois P. Paf-induced release of spasmogens from guinea-pig lungs. Br J Pharmacol 1989; 96: 153–62.PubMedGoogle Scholar
  255. 255.
    Stimler-Gerard NP. Parasympathetic stimulation as a mechanism for platelet-activating factor-induced contractile responses in the lung. J Pharmacol Exp Ther 1986; 237: 209–13.PubMedGoogle Scholar
  256. 256.
    Leff AR, White SR, Munoz NM, Popovich KJ, Shioya T, Stimler-Gerard NP. Parasympathetic involvement in PAF-induced contraction in canine trachealis in vivo. J Appl Physiol 1987; 62: 599–605.PubMedGoogle Scholar
  257. 257.
    Johnson PRA, Armour CL, Black JL. The action of platelet activation factor and its antagonism by WEB 2086 on human isolated airways. Eur Respir J 1990; 3: 55–60.PubMedGoogle Scholar
  258. 258.
    Johnson PRA, Black JL, Armour CL. Platelet-activating factor-induced contraction of human isolated bronchus. Eur Respir J 1992; 5: 970–4.PubMedGoogle Scholar
  259. 259.
    Manzini S, Meini S. Involvement of capsaicin-sensitive nerves in the bronchomotor effects of arachidonic acid and melittin: a possible role for lipoxin A4. Br J Pharmacol 1991; 103: 1027–32.PubMedGoogle Scholar
  260. 260.
    Rogers DF, Alton EWFW, Aursudkij B, Boschetto P, Dewar A, Barnes PJ. Effect of platelet activating factor on formation and composition of airway fluid in the guinea-pig trachea. J Physiol 1990; 431: 643–58.PubMedGoogle Scholar
  261. 261.
    Yukawa T, Read RC, Kroegel C, Rutman A, Chung KF, Wilson R, et al. The effects of activated eosinophils and neutrophils on guinea pig airway epithelium in vitro. Am J Respir Cell Mol Biol 1990; 2: 341–53.PubMedGoogle Scholar
  262. 262.
    Webber SE, Morikawa T, Widdicombe JG. Platelet-activating factor relaxes ferret tracheal smooth muscle and reduces transepithelial potential difference in vitro. Br J Pharmacol 1992; 105: 223–9.PubMedGoogle Scholar
  263. 263.
    Pretolani M, Lefort J, Leduc D, Vargaftig BB. Effect of human recombinant interleukin-5 on in vitro responsiveness to PAF of lung from actively sensitized guinea-pigs. Br J Pharmacol 1992; 106: 677–84.PubMedGoogle Scholar
  264. 264.
    Pretolani M, Lefort J, Dumarey C, Vargaftig BB. Role of lipoxygenase metabolites for the hyper-responsiveness to platelet-activating factor of lungs from actively sensitized guinea pigs. J Pharmacol Exp Ther 1989; 248: 353–9.PubMedGoogle Scholar
  265. 265.
    Arima M, Yukawa T, Terashi Y, Sagara H, Makino S. Platelet activating factor (PAF)-induced late asthmatic response in sensitized but not in non-sensitized guinea pigs. Arerugi 1992; 41: 607–14.PubMedGoogle Scholar
  266. 266.
    Kadiri C, Leduc D, Lefort J, Imaizumi A, Vargaftig BB. Guinea-pig treatment with pertussis toxin suppresses macrophage-dependent bronchoconstriction by fMLP and fails to inhibit the effects of PAF. Br J Pharmacol 1992; 107: 1029–36.PubMedGoogle Scholar
  267. 267.
    Arreto CD, Bureau MF, Imaizumi A, Vargaftig BB. Pharmacological differentiation by pertussis toxin in the in vivo acute responses to fMLP and PAF in guinea-pig lungs. Br J Pharmacol 1993; 108: 412–7.PubMedGoogle Scholar
  268. 268.
    Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986; ii: 189–92.CrossRefGoogle Scholar
  269. 269.
    Wardlaw AJ, Chung KF, Moqbel R, MacDonald AJ, Hartnell A, McCusker M, et al. Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils: relationship to bronchoconstriction and changes in airway responsiveness. Am Rev Respir Dis 1990; 141: 386–92.PubMedGoogle Scholar
  270. 270.
    Kaye MG, Smith LJ. Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141: 993–7.PubMedGoogle Scholar
  271. 271.
    Rubin AH, Smith LJ, Patterson R. The bronchoconstrictor properties of platelet-activating factor in humans. Am Rev Respir Dis 1987; 136: 1145–51.PubMedCrossRefGoogle Scholar
  272. 272.
    Chung KF, Barnes PJ. Effects of platelet activating factor on airway calibre, airway responsiveness, and circulating cells in asthmatic subjects. Thorax 1989; 44: 108–15.PubMedCrossRefGoogle Scholar
  273. 273.
    Hopp RJ, Bewtra AK, Nabe M, Agrawal DK, Townley RG. Effect of PAF-acether inhalation on nonspecific bronchial reactivity and adrenergic response in normal and asthmatic subjects. Chest 1990; 98: 936–41.PubMedCrossRefGoogle Scholar
  274. 274.
    Hopp RJ, Bewtra AK, Agrawal DK, Townley RG. Effect of platelet-activating factor inhalation on nonspecific bronchial reactivity in man. Chest 1989; 96: 1070–2.PubMedCrossRefGoogle Scholar
  275. 275.
    Spencer DA, Green SE, Evans JM, Piper PJ, Costello JF. Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man. Clin Exp Allergy 1990; 20: 525–32.PubMedCrossRefGoogle Scholar
  276. 276.
    Lai CKW, Jenkins JR, Polosa R, Holgate ST. Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects. J Appl Physiol 1990; 68: 919–26.PubMedGoogle Scholar
  277. 277.
    Gebremichael I, Leuenberger P. Platelet-activating factor does not induce bronchial hyperreactivity in nonasthmatic subjects. Respiration 1992; 59: 193–6.PubMedCrossRefGoogle Scholar
  278. 278.
    Christman BW, Lefferts PL, Snapper JR. Effect of platelet-activating factor on aerosol histamine responsiveness in awake sheep. Am Rev Respir Dis 1987; 135: 1267–70.PubMedGoogle Scholar
  279. 279.
    Soler M, Mansour E, Fernandez A, D’Brot J, Ahmed T, Abraham WM. PAF-induced airway responses in sheep: effects of a PAF antagonist and nedocromil sodium. J Allergy Clin Immunol 1990; 85: 661–8.PubMedCrossRefGoogle Scholar
  280. 280.
    Chung KF, Aizawa H, Leikauf GD, Ueki IF, Evans TW, Nadel JA. Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. J Pharmacol Exp Ther 1986; 236: 580–4.PubMedGoogle Scholar
  281. 281.
    Touvay C, Pfister A, Vilain B, Carre C, Page CP, Lellouch-Tubiana A, et al. Effect of long-term infusion of platelet-activating factor on pulmonary responsiveness and morphology in the guinea-pig. Pulm Pharmacol 1991; 4: 43–51.PubMedCrossRefGoogle Scholar
  282. 282.
    Mencia-Huerta JM, Touvay C, Pfister A, Braquet P. Effèt de l’administration chronique du “platelet activating factor” sur la réponse et la morphologie pulmonaires chez le cobaye. Allergy Immunol 1988; 22 (Suppl. 10): 21–4.Google Scholar
  283. 283.
    Robertson DN, Coyle AJ, Rhoden KJ, Grandordy B, Page CP, Barnes PJ. The effect of platelet-activating factor on histamine and muscarinic receptor function in guinea pig airways. Am Rev Respir Dis 1988; 137: 1317–22.PubMedGoogle Scholar
  284. 284.
    Coyle AJ, Spina D, Page CP. PAF-induced bronchial hyperresponsiveness in the rabbit: contribution of platelets and airway smooth muscle. Br J Pharmacol 1990; 101: 31–8.PubMedGoogle Scholar
  285. 285.
    Barnes PJ, Grandordy BM, Page CP, Rhoden KJ, Robertson DN. The effect of platelet activating factor on pulmonary β-adrenoceptors. Br J Pharmacol 1987; 90: 709–15.PubMedGoogle Scholar
  286. 286.
    Agrawal DK, Bergren DR, Byorth PJ, Townley RG. Platelet-activating factor induces nonspecific desensitization to bronchodilators in guinea pigs. J Pharmacol Exp Ther 1991; 259: 1–7.PubMedGoogle Scholar
  287. 287.
    Webber SE, Morikawa T, Widdicombe JG. PAF-induced muscarinic cholinoceptor hyperresponsiveness of ferret tracheal smooth muscle and gland secretion in vitro. Br J Pharmacol 1992; 105: 230–7.PubMedGoogle Scholar
  288. 288.
    Katsumata U, Miura M, Ichinose M, Kimura K, Takahashi T, Inoue H, et al. Oxygen radicals produce airway constriction and hyperresponsiveness in anesthetized cats. Am Rev Respir Dis 1990; 141: 1158–61.PubMedGoogle Scholar
  289. 289.
    Szarek JL, Schmidt NL. Hydrogen peroxide-induced potentiation of contractile responses in isolated rat airways. Am J Physiol 1990; 258: L232–7.PubMedGoogle Scholar
  290. 290.
    Zoratti EM, Sedgwick JB. Vrtis RR, Busse WW. The effect of platelet-activating factor on the generation of Superoxide anion in human eosinophils and neutrophils. J Allergy Clin Immunol 1991; 88: 749–58.PubMedCrossRefGoogle Scholar
  291. 291.
    Sedgwick JB, Calhoun WJ, Vrtis RF, Bates ME, McAllister PK, Busse WW. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992; 149: 3710–8.PubMedGoogle Scholar
  292. 292.
    Shute JK, Rimmer SJ, Akerman CL, Church MK, Holgate ST. Studies of cellular mechanisms for the generation of Superoxide by guinea-pig eosinophils and its dissociation from granule peroxidase release. Biochem Pharmacol 1990; 40: 2013–21.PubMedCrossRefGoogle Scholar
  293. 293.
    Tashiro K, Xie Z, Ito Y. Effects of PAF on excitatory neuro-effector transmission in dog airways. Br J Pharmacol 1992; 107: 956–63.PubMedGoogle Scholar
  294. 294.
    McManus LM, Pinckard RN. Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit. Am J Pathol 1985; 121: 55–68.PubMedGoogle Scholar
  295. 295.
    Lellouch-Tubiana A, Lefort J, Pirotzky E, Vargaftig BB, Pfister A. Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br J Exp Pathol 1985; 66: 345–55.PubMedGoogle Scholar
  296. 296.
    Lellouch-Tubiana A, Lefort J, Simon MT, Pfister A, Vargaftig BB. Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration: modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis 1988; 137: 948–54.PubMedGoogle Scholar
  297. 297.
    Camussi G, Pawlowski I, Tetta C, Roffinello C, Alberton M, Brentjens J, et al. Acute lung inflammation induced in the rabbit by local instillation of 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phsphorylcholine or of native platelet-activating factor. Am J Pathol 1983; 112: 78–88.PubMedGoogle Scholar
  298. 298.
    Colditz IG, Topper EK. The effect of systemic treatment with platelet-activating factor on the migration of eosinophils to lung, pleural and peritoneal cavities in the guinea pig. Int Arch Allergy Appl Immunol 1991; 95: 94–6.PubMedCrossRefGoogle Scholar
  299. 299.
    Sanjar S, Aoki S, Boubekeur K, Burrows L, Colditz I, Chapman I, et al. Inhibition of PAF-induced eosinophil accumulation in pulmonary airways of guinea pigs by anti-asthma drugs. Jpn J Pharmacol 1989; 51: 167–72.PubMedCrossRefGoogle Scholar
  300. 300.
    Pedersen KE, Rigby PJ, Goldie RG. Quantitative assessment of increased airway microvascular permeability to 125I-labelled plasma fibrinogen induced by platelet activating factor and bradykinin. Br J Pharmacol 1991; 104: 128–32.PubMedGoogle Scholar
  301. 301.
    Luts A, Sundler F, Erjefalt I, Persson CGA. The airway epithelial lining in guinea pigs is intact promptly after the mucosal crossing of a large amount of plasma exudate. Int Arch Allergy Appl Immunol 1990; 91: 385–8.PubMedCrossRefGoogle Scholar
  302. 302.
    Rogers DF, Boschetto P, Barnes PJ. Plasma exudation: correlation between Evans blue dye and radiolabeled albumin in guinea pig airways in vivo. J Pharmacol Methods 1989; 21: 309–15.PubMedCrossRefGoogle Scholar
  303. 303.
    Evans TW, Dent G, Rogers DF, Aursudkij B, Chung KF, Barnes PJ. Effect of a PAF antagonist, WEB 2086, on airway microvascular leakage in the guinea pig and platelet aggregation in man. Br J Pharmacol 1988; 94: 164–8.PubMedGoogle Scholar
  304. 304.
    O’Donnell SR, Erjefalt I. Persson CGA. Early and late tracheobronchial plasma exudation by platelet-activating factor administered to the airway mucosal surface in guinea pigs: effects of WEB 2086 and enprofylline. J Pharmacol Exp Ther 1990; 254: 65–70.PubMedGoogle Scholar
  305. 305.
    Evans TW, Rogers DF, Aursudkij B, Chung KF, Barnes PJ. Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig. Clin Sci 1989; 76: 479–85.PubMedGoogle Scholar
  306. 306.
    Brokaw JJ, Prow DM, Kirsch CM, White GW. Effects of platelet-activating factor on vascular permeability and granulocyte recruitment in the rat trachea. Lung 1991; 169: 109–19.PubMedCrossRefGoogle Scholar
  307. 307.
    O’Donnell SR, Barnett CJ. Microvascular leakage to platelet activating factor in guinea-pig trachea and bronchi. Eur J Pharmacol 1987; 138: 385–96.PubMedCrossRefGoogle Scholar
  308. 308.
    Burhop KE, Garcia JG, Selig WM, Lo SK, van der Zee H, Kaplan JE, et al. Platelet-activating factor increases lung vascular permeability to protein. J Appl Physiol 1986; 61: 2210–7.PubMedGoogle Scholar
  309. 309.
    Olson NC, Joyce PB, Fleisher LN. Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs. Am J Physiol 1990; 258: H1674–86.PubMedGoogle Scholar
  310. 310.
    Shibamoto T, Yamaguchi Y, Hayashi T, Jr., Sacki Y, Kawamoto M, Koyama S. PAF increases capillary pressure but not vascular permeability in isolated blood-perfused canine lungs. Am J Physiol 1993; 264: H1454–9.PubMedGoogle Scholar
  311. 311.
    Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982; 218: 286–8.PubMedCrossRefGoogle Scholar
  312. 312.
    Imai T, Vercellotti GM, Moldow CF, Jacob HS, Weir EK. Pulmonary hypertension and edema induced by platelet-activating factor in isolated, perfused rat lungs are blocked by BN 52021. J Lab Clin Med 1988; 111: 211–7.PubMedGoogle Scholar
  313. 313.
    Chen CR, Voelkel NF, Chang SW. PAF potentiates protamine-induced lung edema: role of pulmonary venoconstriction. J Appl Physiol 1990; 68: 1059–68.PubMedCrossRefGoogle Scholar
  314. 314.
    Worthen GS, Goins AJ, Mitchel BC, Larsen GL, Reeves JR, Henson PM. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. Chest 1983; 83: Suppl. 13S–5S.PubMedGoogle Scholar
  315. 315.
    Salzer WL, McCall CE. Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury. J Clin Invest 1990; 85: 1135–43.PubMedCrossRefGoogle Scholar
  316. 316.
    Mojarad M, Hamasaki Y, Said SI. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema: a preliminary report. Bull Eur Physiopathol Respir 1983; 19: 253–6.PubMedGoogle Scholar
  317. 317.
    Bolin RW, Martin TR, Albert RK. Lung endothelial and epithelial permeability after platelet-activating factor. J Appl Physiol 1987; 63: 1770–5.PubMedGoogle Scholar
  318. 318.
    Bloom JW, Quan SF, Halonen M, Witten ML, Lernen RJ, Patton DD. Intravenous platelet activating factor does not affect lung epithelial permeability. Res Commun Chem Pathol Pharmacol 1987; 58: 405–8.PubMedGoogle Scholar
  319. 319.
    Webber SE, Widdicombe JG. The transport of albumin across the ferret in vitro trachea. J Physiol 1989; 408: 457–72.PubMedGoogle Scholar
  320. 320.
    Price AM, Webber SE, Widdicombe JG. Albumin transport across the rabbit trachea in vitro. J Appl Physiol 1989; 65: 914–20.CrossRefGoogle Scholar
  321. 321.
    Lundgren JD, Kaliner M, Logun C, Shelhamer JH. Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human expiants: involvement of the lipoxygenase pathway. Agents Actions 1990; 30: 329–37.PubMedCrossRefGoogle Scholar
  322. 322.
    Rieves RD, Goff J, Wu T, Larivee P, Logun C, Shelhamer JH. Airway epithelial cell mucin release: immunologic quantitation and response to platelet-activating factor. Am J Respir Cell Mol Biol 1992; 6: 158–67.PubMedGoogle Scholar
  323. 323.
    Shimura S, Sasaki T, Ishihara H, Satoh M, Masuda T, Sasaki H, et al. Airway hyperresponsiveness and mucus secretion. Nippon Kyobu Shikkan Gakkai Zasshi 1990; 28: 1299–304.PubMedGoogle Scholar
  324. 324.
    Widdicombe JG, Ueki IF, Emery D, Margolskee S, Yergey J, Nadel JA. Release of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human. Am J Physiol 1989; 257: L361–5.PubMedGoogle Scholar
  325. 325.
    Sestini P, Bienenstock J, Crowe SE, Marshall JS, Stead RH, Kakuta Y, et al. Ion transport in rat tracheal epithelium in vitro: Role of capsaicin-sensitive nerves in allergic reactions. Am Rev Respir Dis 1990; 141: 393–7.PubMedGoogle Scholar
  326. 326.
    Tamaoki J, Shaki N, Isono K, Kanemura T, Yamawaki I, Takizawa T. Effects of platelet-activating factor on bioelectric properties of cultured tracheal and bronchial epithelia. J Allergy Clin Immunol 1991; 87: 1042–9.PubMedCrossRefGoogle Scholar
  327. 327.
    Kuitert LM, Hui K-P, Uthayarkumar S, Burke W, Newland AC, Uden S, et al. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993; 147: 82–6.PubMedCrossRefGoogle Scholar
  328. 328.
    Freitag A, Watson RM, Matsos G, Eastwood C, O’Byrne PM. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax 1993; 48: 594–8.PubMedCrossRefGoogle Scholar
  329. 329.
    Hsieh K-H. Effects of PAF antagonist, BN 52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. Chest 1991; 99: 877–82.PubMedCrossRefGoogle Scholar
  330. 330.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, et al. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736. J Pharmacol Exp Ther 1991; 259: 78–85.PubMedGoogle Scholar
  331. 331.
    Fukuda T, Akutsu I, Amagai M, Numao T, Motojima S, Makino S. Antigen-induced biphasic eosinophil infiltration in the airways of actively sensitized guinea pigs and its inhibition by PAF antagonist and cyclosporin A. Arerugi 1990; 39: 548–52.PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 1995

Authors and Affiliations

  • Gordon Dent
    • 1
  1. 1.Zentrum für Pneumologie und Thoraxchirurgie, LVA Freie und Hansestadt HamburgKrankenhaus GrosshansdorfGermany

Personalised recommendations